ESR1 and breast carcinoma: Recent data also indicated how immunophenotype relates to genomic abnormalities, where CD8+ T-cells were found to be more abundant with PI3KCA mutations in ER+ breast cancer [24], which may partially explain the findings of higher TILs in poorly responsive neoadjuvant aromatase inhibition (AI) in ER+ [25].